Glenmark Pharmaceuticals announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml, through its US subsidiary. The drug is bioequivalent and therapeutically equivalent to Vitamin K Injectable Emulsion USP, 10 mg/ml, manufactured by Hospira, Inc.
Phytonadione is a crucial medication used to treat blood clotting disorders caused by Vitamin K deficiency. The newly launched drug is designed as a single-dose ampule and meets strict quality and efficacy standards to match the reference drug.
Marc Kikuchi, President and Business Head of Glenmark North America, emphasized the company's commitment to offering affordable and quality alternatives for patients.
"We are excited to announce the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml, which strengthens our institutional product portfolio and ensures access to essential medications at affordable prices," Kikuchi stated.
The market for Vitamin K1 Injectable Emulsion USP, 10 mg/ml, recorded annual sales of approximately $19.7 million, according to IQVIA sales data for the 12 months ending November 2024. Glenmark's new product aims to capture a significant share of this market while meeting the medical needs of patients with blood clotting issues.
In addition to the product launch, Glenmark recently shared promising data from the Phase 1 clinical study of Trispecific TREAT Antibody, ISB 2001. This study showcased its potential in treating heavily pretreated Multiple Myeloma patients.
High Overall Response Rate (ORR): An impressive 75% ORR was observed across all doses tested.
Stringent Complete Remission (sCR): A stringent CR and complete remission rate of 20% were achieved.
Dosing Range: The doses ranged from 0.005 to 1.2 mg per kg.
These results indicate that ISB 2001 may compare favorably with approved bispecific antibody therapies, offering durable responses and a favorable safety profile.
Glenmark Pharma shares showed a positive trend, trading 0.5% higher at ₹1,511.15 apiece on Tuesday, January 21. The stock has delivered remarkable growth, gaining 75.92% in the past year, reflecting investor confidence in the company's innovative product pipeline and strategic launches.
The launch of Phytonadione Injectable Emulsion underscores Glenmark's commitment to innovation and addressing unmet medical needs. Combined with the promising clinical trial results for ISB 2001, the company continues to solidify its reputation as a leader in affordable healthcare solutions.
Conclusion
Glenmark Pharmaceuticals continues to demonstrate its commitment to providing affordable and high-quality healthcare solutions with the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml. This development not only addresses critical medical needs for treating blood clotting disorders caused by Vitamin K deficiency but also strengthens Glenmark's position in the institutional product market.
The promising clinical trial results of ISB 2001 further highlight Glenmark's innovative approach to tackling complex medical conditions like Multiple Myeloma. Coupled with strong stock performance and strategic advancements, Glenmark is paving the way for a robust and sustainable future in the pharmaceutical industry.